Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

35.7%

5 terminated/withdrawn out of 14 trials

Success Rate

64.3%

-22.2% vs industry average

Late-Stage Pipeline

86%

12 trials in Phase 3/4

Results Transparency

133%

12 of 9 completed trials have results

Key Signals

12 with results

Enrollment Performance

Analytics

Phase 3

12(85.7%)

Phase 2

1(7.1%)

Phase 1

1(7.1%)

14Total

Phase 3(12)

Phase 2(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (14)

Showing 14 of 14 trials

NCT04002661Phase 2Terminated

Hypoactive Sexual Desire Disorder in Males

Role: collaborator

NCT01040208Phase 3Terminated

12 Week Safety Trial of Flibanserin in Depressed Women Taking an SSRI or SNRI With Decreased Sexual Desire and Distress

Role: lead

NCT00360555Phase 3Completed

Uptitration Trial of Flibanserin Versus Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder

Role: lead

NCT00360529Phase 3Completed

24-week Placebo-controlled Trial of Flibanserin Once Daily in Premenopausal Women With Hypoactive Sexual Desire Disorder

Role: lead

NCT00360243Phase 3Completed

6-mo. Min Eff Dose of Flibanserin: 25 v 50 mg Bid v 50 mg hs v Pbo in Younger Women in NA

Role: lead

NCT00601367Phase 3Completed

Flibanserin Evaluation Over 28 Additional Weeks in Hypoactive Sexual Desire Disorder

Role: lead

NCT01057901Phase 3Terminated

Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women in North America

Role: lead

NCT00441558Phase 3Terminated

A One-year Safety Study of Flibanserin to Treat Pre-Menopausal Women With Hypoactive Sexual Desire Disorder (HSDD).

Role: lead

NCT00996372Phase 3Completed

Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women

Role: lead

NCT00491829Phase 3Completed

Flibanserin Versus Placebo in Premenopausal Women With HSDD

Role: lead

NCT01188603Phase 1Completed

Pharmacokinetics of Flibanserin in Postmenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)

Role: lead

NCT00996164Phase 3Completed

Fixed 100 mg Every Evening of Flibanserin vs Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder

Role: lead

NCT01103362Phase 3Terminated

A 28-week Safety Study of Flibanserin in Pre- and Postmenopausal Women With Hypoactive Sexual Desire Disorder

Role: lead

NCT00277914Phase 3Completed

Flibanserin Randomized Withdrawal Trial in Pre-menopausal Women

Role: lead

All 14 trials loaded